Silicon Valley Billionaires Want to Reverse Aging: First Human Trial Offers Encouraging Signs

Jeff Bezos, Peter Thiel, Yuri Milner and Sam Altman are investing in one of the most ambitious areas of modern biotechnology: cellular reprogramming. Scientists hope the technology will allow aging cells to return to a more youthful state and, eventually, help combat a wide range of age-related diseases. The first clinical trial of the approach in humans is now underway, and preliminary findings look promising, Business Insider reports.

As the body ages, it inevitably faces a range of problems, from worn-out joints and clogged arteries to declining eyesight. Researchers are searching for ways not merely to slow these processes but to address them at the cellular level — almost as if they could reset the body’s biological machinery.

That is the premise behind investments by some of Silicon Valley’s wealthiest backers, who are funding biotechnology companies developing potential rejuvenation therapies.

Until recently, cellular reprogramming had been tested primarily in animals. Experiments have shown signs of rejuvenation in mice and monkeys. In 2026, however, the technology moved into human clinical trials for the first time.

First Human Trial: Can Vision Be Restored?

The clinical trial is being conducted by Life Biosciences. Its experimental therapy is designed for patients with glaucoma, an eye disease that can lead to irreversible vision loss.

On Thursday, the company released its first safety data. At the time, three patients had received the experimental treatment. The therapy was administered directly into the eye, after which participants took daily antibiotics for eight weeks to activate the cellular rejuvenation factors.

According to the company, none of the three patients experienced serious adverse effects. Life Biosciences said the treatment was generally well tolerated.

The approach involves delivering genetic instructions into cells to help return them to a more youthful state. Scientists are studying similar mechanisms in connection with processes involved in embryonic development and the function of stem cells.

The initial findings also offered preliminary grounds for hope that vision could improve: two of the three participants showed notable improvements in the results of standard ophthalmological examinations.

Experts, however, are urging caution. Dr. James Tsai, president of the New York Eye and Ear Infirmary of Mount Sinai and a glaucoma specialist who was not involved in the study, described the findings as encouraging but emphasized that they remain preliminary.

According to Tsai, improved vision does not necessarily mean the treatment has restored damaged eye tissue. It is possible that the therapy simply improved the transmission of electrical signals in surviving cells in patients who still had some residual vision.

Following the initial encouraging results, an independent safety monitoring board approved a threefold increase in the dosage for the next group of participants. The higher dose could potentially improve the treatment’s effectiveness, but its safety and efficacy still need to be evaluated.

Could Cellular Rejuvenation Become a Universal Treatment?

If further research confirms the technology’s effectiveness, its potential applications could extend far beyond eye care.

Life Biosciences points to animal studies exploring cellular reprogramming as a possible way to address various age-related conditions. Areas of interest include arthritis, high blood pressure, fatty liver disease and neurodegenerative disorders, including Alzheimer’s disease.

Michael Ringel, the company’s chief operating officer, believes the technology could eventually become a broadly applicable tool for tackling age-related conditions.

“We believe it could potentially become a kind of universal key to addressing a wide range of age-related diseases,” he said. Ringel emphasized, however, that this possibility still needs to be demonstrated in clinical trials.

Who Else Is Preparing for Human Trials?

Life Biosciences remains the first company to have begun testing cellular reprogramming in a human clinical trial. But competitors in Silicon Valley are already preparing for the next stages of the race to extend healthy lifespan.

Altos Labs, backed by Jeff Bezos, recruited clinical trials expert Joan Mannick last year and appointed her head of product development. According to longevity scientist Jamie Justice, who leads the Healthspan initiative at XPRIZE, the appointment could signal that the company is preparing to move into clinical trials.

Another contender is New Limit. The company raised $435 million in a Series C funding round led by Peter Thiel’s Founders Fund. New Limit aims to begin its first trials of a therapy designed to reprogram liver cells in 2027.

Sam Altman-backed Retro Biosciences is also pursuing its own research.

For now, it is far too early to declare victory over aging. Life Biosciences’ initial results are based on just three patients, and the improvements in vision seen in two participants do not prove that the treatment fully restores tissue or works against other age-related diseases.

But if subsequent studies confirm these early observations, cellular reprogramming could open up a new frontier in medicine — shifting the focus from treating individual diseases to targeting the biological mechanisms of aging itself.